Alkermes plc, listed on the Nasdaq, will present its second‑quarter 2026 financial results today. The earnings call begins at 8:00 a.m. ET (1:00 p.m. BST) and will be streamed live from the Investors section of the company’s website.
U.S. participants can join by dialing +1 877 407 2988, while international callers should use +1 201 389 0923. A recording of the discussion will be posted on the same site after the event.
Product portfolio and pipeline
The firm currently markets medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its development programme includes late‑stage candidates targeting narcolepsy and idiopathic hypersomnia, as well as early‑stage orexin‑2 receptor agonists aimed at treating ADHD and fatigue linked to multiple sclerosis and Parkinson’s disease.
Alkermes is incorporated in Ireland, operates a corporate office and research centre in Massachusetts, and runs a manufacturing plant in Ohio.
For Canadians holding U.S.‑listed biotech equities, the update provides a window into how the company is progressing toward commercialising its pipeline and the likely effect on future revenue, especially as the sector contends with regulatory and reimbursement hurdles.
The complete earnings release and accompanying presentation are available through Alkermes’ investor‑relations portal.